420 results on '"Munakata, Wataru"'
Search Results
2. Clinicopathological differences between T-lymphoblastic leukemia/lymphoma, early T-precursor lymphoblastic leukemia/lymphoma, and mixed-phenotype acute leukemia with T lineage: An analysis of 41 adult cases
3. Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies
4. Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma
5. The kappa/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype
6. Pathogenesis of Gastrointestinal Follicular Lymphomas: Consideration Based on Histopathology and Endoscopic Findings
7. Effects of body compositions on the associations between ferritin and diabetes parameters among Japanese community dwellers
8. Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia–lymphoma
9. Usefulness of hematopoietic progenitor cell monitoring to predict autologous peripheral blood stem cell harvest timing: A single-center retrospective study
10. Adult T-Cell Leukemia-Lymphoma
11. The Association between Gut Microbiota and Depression in the Japanese Population
12. An update on the developments in the treatment of adult T-cell leukemia–lymphoma: current knowledge and future perspective
13. P1086: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE
14. P1520: PROGNOSTIC IMPACT OF FEBRILE NEUTROPENIA AND DOSE INTENSITY OF R-CHOP THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA, A SUPPLEMENTARY ANALYSIS OF JCOG0601
15. Clinicopathological characteristics of diffuse large B-cell lymphoma involving small and large intestines: an analysis of 126 patients
16. New Agents of Adult T-cell Leukemia/Lymphoma (ATL)
17. Multiple myeloma with IGH-FGFR3 rearrangement progressing as testicular plasmacytoma during carfilzomib treatment
18. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma
19. Mucosa-associated lymphoid tissue lymphoma with t(11;18)(q21;q21) translocation: long-term follow-up results
20. CD3+ CD56+ EBER1+ atypical extraosseous plasmacytoma of the nasal cavity
21. Comparison of clinicopathologic characteristics of gastric follicular lymphomas and duodenal follicular lymphomas
22. Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
23. Adult T-Cell Leukemia-Lymphoma
24. Diagnostic clues of BCL2-negative, faint, or controversial follicular lymphomas: A study of 103 cases
25. Distribution of malignant lymphomas in the anterior mediastinum: a single-institution study of 76 cases in Japan, 1997–2016
26. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia
27. Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies
28. Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)
29. Variegated RHOA mutations in adult T-cell leukemia/lymphoma
30. Marked erythroblastosis in myelodysplastic syndrome induced by gastric hemorrhaging
31. Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma
32. Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment
33. Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era
34. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma
35. Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma
36. SY08-2 The development of BCR signaling pathway-targeted therapy for B-cell malignancies
37. CD3-and CD20-negative extramedullary non-Hodgkin leukemia/lymphoma: a histopathological study of 118 cases
38. Successful full-dose DeVIC therapy in a patient with advanced-stage extranodal natural killer/T-cell lymphoma refractory to l-asparaginase
39. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers
40. Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy
41. Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma
42. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies
43. Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia
44. The outcome of watchful waiting in patients with previously treated follicular lymphoma
45. A Case of Diffuse Large B-cell Lymphoma with Portal Vein, Splenic Vein, and Superior Mesenteric Vein Tumor Embolization Diagnosed by Percutaneous Transhepatic Portal Vein Biopsy
46. The role of surveillance computed tomography in patients with follicular lymphoma
47. Two -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemiatwo -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemia
48. The infiltration of classical Hodgkin lymphoma cells into pleural effusion
49. Diagnostic utility and prognostic significance of the Ki‐67 labeling index in diffuse large B‐cell lymphoma transformed from follicular lymphoma: a study of 76 patients
50. Impact of Progression-Free Survival at 24 Months on Subsequent Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Supplementary Analysis of JCOG0601
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.